Ariad leverages Iclusig to access cash
This article was originally published in Scrip
Executive Summary
You may also be interested in...
Ariad Retreats From Europe Via Incyte Deal
Ariad Pharmaceuticals Inc., a company which has been plagued by setbacks for its leading marketed product, Iclusig (ponatinib), has completed the sale of its European business to Incyte Corp. for $140m.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.